Trial Profile
A Phase I, Open Label Crossover Study to Evaluate the Effect of Etravirine on GSK1265744 Pharmacokinetics in Healthy Adult Subjects.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 20 Aug 2023
Price :
$35
*
At a glance
- Drugs Cabotegravir (Primary) ; Etravirine
- Indications HIV infections; HIV-1 infections
- Focus Pharmacokinetics
- Sponsors GlaxoSmithKline; GSK
- 06 Oct 2009 Actual end date (Sep 2009) added as reported by ClinicalTrials.gov.
- 06 Oct 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 29 Aug 2009 Additional lead trial investigator identified as reported by ClinicalTrials.gov.